NCT07711184招募中1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 320
- 试验地点
- 13
- 主要终点
- the recommended Phase II dose (RP2D)
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and the recommended Phase II dose (RP2D) of HRS-7525.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participating in this clinical study, understanding the study procedures, and being able to provide written informed consent;
- •Males, aged 18-80 years (inclusive; no upper age limit in the expansion stage);
- •Eastern Cooperative Oncology Group (ECOG) Performance Status score 0-1;
- •Life expectancy ≥12 weeks;
- •Histologically or cytologically confirmed adenocarcinoma of the prostate, without a diagnosis of neuroendocrine carcinoma or small cell carcinoma;
- •Presence of metastatic lesions confirmed by CT/MRI or radionuclide bone scan (99mTc);
- •Male participants with a female partner of childbearing potential must agree to refrain from sperm donation and use appropriate contraceptive measures from the time of signing the informed consent form until 3 months after the last dose of the investigational product；
排除标准
- •Planning to receive any other anti-tumor therapy during this study;
- •Having received chemotherapy, targeted therapy, immunotherapy, live attenuated vaccines, radiotherapy, or surgery, etc., less than 4 weeks prior to the start of study treatment; participating in another clinical study within 4 weeks prior to the start of study treatment (calculated from the last use of the investigational drug);
- •Damage caused by any prior anti-tumor treatment has not recovered to Grade ≤ 1 or the criteria specified in this study (graded according to NCI-CTCAE 6.0; excluding alopecia and other adverse events deemed tolerable by the investigator);
- •Participants with poorly controlled hypertension, and those with a history of hypertensive crisis or hypertensive encephalopathy;
- •Known tumor metastasis to the central nervous system or meningeal metastasis, or participants with a history of primary central nervous system tumor;
- •Severe bone injury caused by tumor bone metastases as judged by the investigator, including poorly controlled severe bone pain, pathological fractures at critical sites and spinal cord compression that have occurred within the last 6 months or are highly likely to occur in the near future;
- •Presence of one of the various factors affecting oral drug administration or active gastrointestinal diseases or other conditions that may significantly affect drug absorption, distribution, metabolism or excretion;
- •Known allergy or intolerance to HRS-7525 or its excipients;
- •Presence of active heart disease within 6 months prior to the first dose of the study, including severe/unstable angina pectoris, myocardial infarction, symptomatic congestive heart failure and ventricular arrhythmia requiring drug therapy;
- •Any other malignant tumor within 5 years prior to the first dose in the study (excluding carcinoma in situ that has been completely relieved and malignant tumors that are judged by the investigator as slowly progressive);
- •Presence of active hepatitis B (HBsAg positive and HBV DNA ≥ 500 IU/mL), hepatitis C (positive HCV antibody and HCV RNA above the lower limit of detection of the analytical method); or participants with severe infections requiring control with antibiotics, antivirals, or antifungals;
- •History of immunodeficiency (including positive HIV test, or other acquired or congenital immunodeficiency disorders) or history of organ transplantation;
- •Presence of other factors that may affect the study results or result in premature discontinuation of this study as judged by the investigator, such as alcoholism, drug abuse, presence of other severe diseases (including mental illness) requiring concomitant treatment, significant laboratory abnormalities, family or social factors, and other conditions that may affect the safety of participants or the collection of study data.
研究组 & 干预措施
HRS-7525 tablets
Experimental
干预措施: HRS-7525 tablets (Drug)
结局指标
主要结局
the recommended Phase II dose (RP2D)
时间窗: From the signing of the informed consent to the end of the safety follow-up period of each subject ，about 13 months
dose limiting toxicity (DLT)
时间窗: a single-dose run-in period (2 days) and 21 days after the first administration of each subject
the maximum tolerated dose (MTD)
时间窗: From the signing of the informed consent to the end of the safety follow-up period of each subject ，about 13 months
次要结局
未报告次要终点
研究者
研究点 (13)
Loading locations...
相似试验
招募中
1 期
Phase I Study of HRS-3005 in B-cell MalignanciesNCT07556822Jiangsu HengRui Medicine Co., Ltd.190
招募中
3 期
Phase III Study of HRS-7535 for Hypertension With Overweight or ObesityHypertension With Overweight or ObesityNCT07528027Shandong Suncadia Medicine Co., Ltd.648
已完成
不适用
Safety Evaluation of HORS-051511 in Healthy AdultsCTRI/2023/12/060476Himalaya Wellness Company (HWC)12
尚未招募
2 期
A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.Uncontrolled or Resistant HypertensionNCT07708441Shandong Suncadia Medicine Co., Ltd.914
招募中
1 期
A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative CancerBreast CancerNCT07358377Atridia Pty Ltd.15